Titre :

Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.

Auteur(s) :

Baldini, Capucine [Auteur]
Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] [DITEP]
Charton, E. [Auteur]
Centre Léon Bérard [Lyon]
Schultz, E. [Auteur]
Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale [SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD]
Centre population et développement [CEPED - UMR_D 196]
Auroy, L. [Auteur]
Sciences Po Grenoble-UGA - Institut d'études politiques de Grenoble [IEPG]
Italiano, A. [Auteur]
Institut Bergonié [Bordeaux]
Robert, M. [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Coquan, E. [Auteur]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]
Isambert, N. [Auteur]
Laboratoire de neurosciences expérimentales et cliniques [U 1084] [LNEC [Poitiers]]
Moreau, P. [Auteur]
Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] [UNICANCER/CRLCC-CGFL]
Le Gouill, S. [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Le Tourneau, C. [Auteur]
Institut Curie [Paris]
Ghrieb, Z. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Kiladjian, J. J. [Auteur]
Institut Claudius Regaud [ICR]
Delord, J. P. [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Roca, C. G. [Auteur]
Institut Claudius Regaud [ICR]
Vey, N. [Auteur]
Institut Paoli-Calmettes [IPC]
Barlesi, F. [Auteur]
Centre de Recherche en Cancérologie de Marseille [CRCM]
Lesimple, T. [Auteur]
CRLCC Eugène Marquis [CRLCC]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Soria, J. C. [Auteur]
Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] [DITEP]
Massard, C. [Auteur]
Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] [DITEP]
Besle, S. [Auteur]
Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] [DITEP]

Titre de la revue :

European Society for Medical Oncology

Nom court de la revue :

ESMO Open

Numéro :

7

Pagination :

100468

Date de publication :

2022-05-11

ISSN :

2059-7029

Mot(s)-clé(s) en anglais :

early-phase clinical trials
cancer
older patients
enrollment
access

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background Access to clinical trials and especially early-phase trials (ECT) is an important issue in geriatric oncology. As cancer can be considered an age-related disease because the incidence of most cancers increases ...
Lire la suite >Background Access to clinical trials and especially early-phase trials (ECT) is an important issue in geriatric oncology. As cancer can be considered an age-related disease because the incidence of most cancers increases with age, new drugs should also be evaluated in older patients to assess their safety and efficacy. The EGALICAN-2 study was primarily designed to identify social and/or regional inequalities regarding access to ECT. We focused on the factors of inequalities in access to ECT in older patients. Patients and methods During a 1-year period (2015-2016), a survey was conducted in 11 early-phase units certified by the French National Cancer Institute. Results A total of 1319 patients were included in the analyses: 1086 patients (82.3%) were <70 years and 233 patients (17.7%) were >70 years. The most common tumor types at referral in older patients were gastrointestinal (19.3%), hematological (19.3%), and thoracic tumors (18.0%). Most patients referred to the phase I unit had signed informed consent and the rate was similar across age (92.7% in younger patients versus 90.6% in older patients; P = 0.266). The rate of screening failure was also similar across age (28.5% in younger patients versus 24.3% in older patients; P = 0.219). Finally, in older patients, univariate analyses showed that initial care received in the hospital having a phase I unit was statistically associated with first study drug administration (odds ratio 0.49, 90% confidence interval 0.27-0.88; P = 0.045). Conclusions Older patients are underrepresented in early clinical trials with 17.7% of patients aged ≥70 years compared with the number of new cases of cancer in France (50%). However, when invited to participate, older patients were prone to sign informed consent.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2023-11-15T04:11:58Z
2024-05-03T08:06:50Z